Chemotherapy-induced Thrombocytopenia Clinical Trial
Official title:
A Retrospective Study of the Recombinant Human Interleukin-11 (I) (Baijieyi) for Prevention and Treatment of Chemotherapy-induced Thrombocytopenia in Patients With Malignant Tumor
The aim of this retrospective study is to review and describe the safety and the efficacy of recombinant human interleukin-11 (I) i (Baijieyi), using information already recorded in 20 medical records, The time periods include May 8th of 2008 to december 31st of 2016.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05969158 -
Hetrombopag in Secondary Prevention of XPO-1 Inhibitor-induced Thrombocytopenia in Lymphoma
|
Phase 2 | |
| Active, not recruiting |
NCT03362177 -
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
|
Phase 3 | |
| Recruiting |
NCT05554913 -
Evaluating the Efficacy and Safety of QL0911 in the Prevention of Chemotherapy- Induced Thrombocytopenia
|
Phase 2/Phase 3 | |
| Completed |
NCT05688306 -
To Evaluate Thrombosis Risk in Chemotherapy Patients With Solid Tumors Who Receiving Thrombocytopenia Treatment
|
||
| Completed |
NCT00283439 -
A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06099925 -
The Efficacy and Safety of Hetrombopag as Secondary Prevention to Chemotherapy-induced Thrombocytopenia in Patients With Gynecologic Malignancies
|
Phase 2 | |
| Completed |
NCT03471078 -
Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Active Non-Hematological Cancers
|
Phase 3 | |
| Active, not recruiting |
NCT03976882 -
Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects With Malignancy.
|
Phase 3 | |
| Recruiting |
NCT05772546 -
Avatrombopag vs. Placebo for CIT in GI Malignancies
|
Phase 2 | |
| Not yet recruiting |
NCT05864014 -
Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors.
|
Phase 3 | |
| Terminated |
NCT01345214 -
A Study of the Safety and Efficacy of ONO-7746 in Adult Cancer Patients With Chemotherapy Induced Thrombocytopenia
|
Phase 1 | |
| Completed |
NCT01663441 -
A Phase Ⅲa Study of Genetically Modified Recombinant Human Interleukin-11
|
Phase 3 | |
| Recruiting |
NCT05236582 -
Herombopag for Chemotherapy-induced Thrombocytopenia
|
Phase 2 | |
| Not yet recruiting |
NCT05944211 -
Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia(CIT) in Patients With Acute Myeloid Leukemia
|
Phase 2 | |
| Withdrawn |
NCT03343847 -
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Lymphoma.
|
Phase 3 | |
| Completed |
NCT05851027 -
Evaluating the Efficacy and Safety of QL0911 in Chemotherapy- Induced Thrombocytopenia
|
Phase 2/Phase 3 | |
| Recruiting |
NCT03937154 -
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer
|
Phase 3 | |
| Recruiting |
NCT05218226 -
Avatrombopag for Chemotherapy-induced Thrombocytopenia
|
Phase 2 | |
| Recruiting |
NCT04600960 -
Eltrombopag for Chemotherapy-induced Thrombocytopenia
|
Phase 2 | |
| Completed |
NCT00413283 -
Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)
|
Phase 2 |